Bloodloss: Compare Between the Effect of Topical Tranexamic Acid Versus Hydrogen Peroxide on Blood Loss in Spine Surgeries

Sponsor
Minia University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05152186
Collaborator
(none)
120
1
3
6
20

Study Details

Study Description

Brief Summary

To evaluate the effectiveness of topical TXA in reducing blood loss compared to H2O2 wash.

The primary outcomes :
  1. Estimation of Intraoperative blood loss and blood transfusion.

  2. Recording Postoperative blood drainage.

  3. Comparing Hemoglobin levels (pre and postoperative).

The secondary outcomes :
  1. Surgical site infection (SSI)

  2. Length of hospital stay.

Condition or Disease Intervention/Treatment Phase
  • Drug: Topical Solution
  • Drug: Topical Foam
  • Other: Topical
Phase 3

Detailed Description

Spinal surgery is one of the most commonly performed neuro-surgeries worldwide. Massive blood loss occurs frequently and remains a challenge in complex spinal surgery. Significant intra and postoperative hemorrhage negatively affects patient outcomes by increasing coagulopathy, postoperative hematoma and anemia .The need for allogenic blood transfusions can lead to potential transfusion reactions and infections, in addition to increasing long-term mortality rates. There is an economic disadvantage associated with iatrogenic major blood loss relating to the direct costs of the blood products and intraoperative blood salvage technology and indirect costs of prolonged patient hospitalization and complication management .

Many efforts have focused on achieving better perioperative blood conservation, in particular through prophylactic intravenous administration of antifibrinolytic agents before and during major surgery. Intravenous administration of the inexpensive but highly effective drug as tranexamic acid (TXA) reduces perioperative hemorrhage and the need for blood transfusions by one third in major surgery, including spinal surgery, Included on the list of the World Health Organization (WHO) List of Essential Medicines, TXA has taken its place as a widely used hemostatic agent in the clinical setting .

Tranexamic acid is a synthetic analog of the amino acid lysine. It serves as an antifibrinolytic by reversibly binding four to five lysine receptor sites on plasminogen. This reduces conversion of plasminogen to plasmin, preventing fibrin degradation and preserving the framework of fibrin's matrix structure .Tranexamic acid has roughly eight times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid. Tranexamic acid also directly inhibits the activity of plasmin with weak potency .

Hydrogen peroxide (H2O2) is an inexpensive and readily available option whose hemostatic and antiseptic properties have been separately confirmedin several previous studies .

Study Design

Study Type:
Interventional
Actual Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Prevention
Official Title:
Comparison Between the Effect of Topical Tranexamic Acid Versus Hydrogen Peroxide on Perioperative Blood Loss in Elective Spine Surgeries
Actual Study Start Date :
Jun 1, 2021
Actual Primary Completion Date :
Nov 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: tranexamic acid

Topical hemostatics as tranexamic acid or hydrogen peroxide in wound before skin closure to decrease perioperative blood loss

Drug: Topical Solution
Topical administration
Other Names:
  • Irrigation
  • Drug: Topical Foam
    Topical administration
    Other Names:
  • Disinfectant
  • Other: Topical
    Topical administration
    Other Names:
  • Crystalloid
  • Active Comparator: Hydrogen peroxide

    Topical hemostatics as hydrogen peroxide in wound before skin closure to decrease perioperative blood loss

    Drug: Topical Solution
    Topical administration
    Other Names:
  • Irrigation
  • Drug: Topical Foam
    Topical administration
    Other Names:
  • Disinfectant
  • Other: Topical
    Topical administration
    Other Names:
  • Crystalloid
  • Placebo Comparator: Normal saline

    Hemostasis in spine surgery

    Drug: Topical Solution
    Topical administration
    Other Names:
  • Irrigation
  • Drug: Topical Foam
    Topical administration
    Other Names:
  • Disinfectant
  • Other: Topical
    Topical administration
    Other Names:
  • Crystalloid
  • Outcome Measures

    Primary Outcome Measures

    1. Blood loss estimation [NCT ID not yet assigned] [Within 48 hours]

      Estimation of perioperative blood loss and need of blood transfusion, lab investigations pre and postoperative (hemoglobin (gm/dL), hematocrit (%), Prothrombin concentration (%), INR, platelets). Recording Postoperative blood drainage (in ml). and Comparing Hemoglobin levels (pre and postoperative).

    Secondary Outcome Measures

    1. Complications [7 days]

      Anaemia secondary to blood loss, surgical site infection , length of hospital stay (in days), complications of drugs used in procedure.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • ASA: class II or III

    • Sex: male and female

    • Age: from 20 to 70 years.

    • Type of operation: patient will undergo spinal surgery with a diagnosis of in place spinal trauma, thoracic or lumbar degenerative disease, such as spinal canal stenosis, disc herniation, spondylolisthesis, and/or degenerative scoliosis under general anesthesia.

    Exclusion Criteria:
    • Patients with history of thromboembolic disease or coagulopathy or hereditary bleeding disorders such as factor VIII deficiency, factor IX deficiency, and Von-Willebrand disease.

    • Patients who were taking anticoagulants or antiplatelet drugs.

    • Allergy or hypersensitivity to TXA.

    • A dural tear accompanied by cerebrospinal fluid leakage detected intraoperatively.

    • Spinal cord tumors, head trauma and penetrating spinal cord trauma.

    • The use of intravenous TXA during the perioperative period .

    • Infection at the operative site e.g T.B.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Minia University hospital Minya Egypt

    Sponsors and Collaborators

    • Minia University

    Investigators

    • Study Chair: Amani Khairy, Professor, Faculty of Medicine, Minia University
    • Study Director: Sarah Mohamed, Lecturer, Faculty of Medicine, Minia University
    • Study Director: Walid Zidan, Lecturer, Faculty of Medicine, Minia University
    • Principal Investigator: Nehal Kamal, Master, Faulty of medicine, Minia University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Nehal Kamal Mohamed, Assistant lecturer, Minia University
    ClinicalTrials.gov Identifier:
    NCT05152186
    Other Study ID Numbers:
    • blood loss in spine surgery
    First Posted:
    Dec 9, 2021
    Last Update Posted:
    Dec 9, 2021
    Last Verified:
    Dec 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Nehal Kamal Mohamed, Assistant lecturer, Minia University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 9, 2021